Sugi Predict

Sugi Predict / Compounds / SCHEMBL512668

SCHEMBL512668

SCHEMBL512668

CCOC(=O)Cc1c(F)cc(F)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.43
▸ GAA P10253 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ CASP1 P29466 2/20 0.43
▸ CASP7 P55210 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ RIPK1 Q13546 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ MGAM O43451 1/20 0.40
▸ SI P14410 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16964016 0.86 KDM4E (0.43) LMNAGAASMN1; SMN2KDM4EALDH1A1
SCHEMBL31572389 0.86 MAPK1 (0.44) LMNAGAASMN1; SMN2KDM4EALDH1A1
SCHEMBL9105956 0.82 CYP4F2 (0.47) LMNAGAAKDM4EALDH1A1CASP1
SCHEMBL14744391 0.82 NPC1 (0.43) LMNAGAASMN1; SMN2KDM4EALDH1A1
SCHEMBL14744536 0.82 KMT2A (0.42) LMNAGAASMN1; SMN2KDM4EALDH1A1
SCHEMBL1867904 0.81 NLRP3 (0.54) LMNAGAASMN1; SMN2KDM4EALDH1A1
SCHEMBL155393 0.81 HSP90AB1 (0.46) GAASMN1; SMN2KDM4EALDH1A1CASP1
SCHEMBL18276833 0.81 ALDH1A1 (0.45) LMNAGAASMN1; SMN2KDM4EALDH1A1
SCHEMBL3424184 0.81 RIPK1 (0.44) SMN1; SMN2HPGDRIPK1KMT2AMEN1
SCHEMBL25240413 0.80 CYP4F2 (0.43) LMNAGAAKDM4EALDH1A1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4387957-B1 FUNGICIDAL SUBSTITUTED HETEROCYCLES FMC CORP (US) 2026-04-29 — — EP disclosed
US-20240308968-A1 FUNGICIDAL SUBSTITUTED HETEROCYCLES FMC CORP (US) 2024-09-19 — — US disclosed
EP-4387957-A1 FUNGICIDAL SUBSTITUTED HETEROCYCLES FMC Corporation (US) 2024-06-26 — — EP disclosed
CN-117836274-A Fungicidal substituted heterocyclic compounds FMC公司 2024-04-05 — — CN disclosed
WO-2023023242-A1 FUNGICIDAL SUBSTITUTED HETEROCYCLES FMC CORPORATION (US) 2023-02-23 — — WO disclosed
EP-2668168-B1 COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2017-03-01 — — EP disclosed
EP-2668168-B1 COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2017-03-01 — — EP disclosed
CN-103328451-B Compounds for the reduction of beta-amyloid production BRISTOL MYERS SQUIBB CO 2015-06-10 — — CN disclosed
US-8710061-B2 Compounds for the reduction of β-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2014-04-29 — — US disclosed
US-8710061-B2 Compounds for the reduction of β-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2014-04-29 — — US disclosed
EP-1684763-A1 6-ARYL-7-HALO-IMIDAZO[1,2-A]PYRIMIDINES AS ANTICANCER AGENT Wyeth Holdings Corporation (US) 2006-08-02 — — EP disclosed
US-20060160811-A1 Aryl-condensed 3-arylpridine compounds and use thereof for controlling pathogenic fungi BASF AKTIENGESELLSCHAFT (DE) 2006-07-20 — — US disclosed
EP-1680425-A1 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS Wyeth Holdings Corporation (US) 2006-07-19 — — EP disclosed
EP-1663241-A1 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS Wyeth Holdings Corporation (US) 2006-06-07 — — EP disclosed
US-20050090508-A1 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents WYETH HOLDINGS CORPORATION (US) 2005-04-28 — — US disclosed
WO-2005030775-A1 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS WYETH HOLDINGS CORPORATION (US) 2005-04-07 — — WO disclosed
US-20050075357-A1 5-arylpyrimidines as anticancer agents WYETH (US) 2005-04-07 — — US disclosed
WO-2005030216-A1 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS WYETH HOLDINGS CORPORATION (US) 2005-04-07 — — WO disclosed
WO-2005030218-A1 6-ARYL-7-HALO-IMIDAZO[1,2-A]PYRIMIDINES AS ANTICANCER AGENT WYETH HOLDINGS CORPORATION (US) 2005-04-07 — — WO disclosed
US-20050065167-A1 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents WYETH HOLDINGS CORPORATION (US) 2005-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065167-A1 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents ABCC1, TUBB3, ABCB1 LMNA 2704/4885GAA 1139/4885SMN1; SMN2 1719/4885
US-20060160811-A1 Aryl-condensed 3-arylpridine compounds and use thereof for controlling pathogenic fungi CBR3, C1R, CBR1 LMNA 3126/4885GAA 3514/4885SMN1; SMN2 4360/4885
US-20050075357-A1 5-arylpyrimidines as anticancer agents DPYD, ABCC1, ARF5 LMNA 3562/4885GAA 487/4885SMN1; SMN2 1367/4885
US-20050090508-A1 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents ABCC1, ABCB1, TUBB6 LMNA 3540/4885GAA 436/4885SMN1; SMN2 1517/4885
US-20240308968-A1 FUNGICIDAL SUBSTITUTED HETEROCYCLES CYP1B1, CYP1A1, NOX1 LMNA 3515/4885GAA 492/4885SMN1; SMN2 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.